BACKGROUND AND OBJECTIVES: Disease-specific treatment options for autosomal dominant polycystic kidney disease are limited. Clinical intervention early in life is likely to have the greatest effect. In a 3-year randomized double-blind placebo-controlled phase 3 clinical trial, the authors recently showed that pravastatin decreased height-corrected total kidney volume (HtTKV) progression of structural kidney disease over a 3-year period. However, the underlying mechanisms have not been elucidated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants were recruited nationally from July 2007 through October 2009. Plasma and urine samples collected at baseline, 18 months, and 36 months from 91 pediatric patients enrolled in the above-mentioned clinical trial were subjected to mass spectrometry-based biomarker analysis. Changes in biomarkers over 3 years were compared between placebo and pravastatin-treated groups. Linear regression was used to evaluate the changes in biomarkers with the percent change in HtTKV over 3 years. RESULTS: Changes in plasma concentrations of proinflammatory and oxidative stress markers (9- hydroxyoctadecadienoic acid, 13-hydroxyoctadecadienoic acid, and 15-hydroxyeicosatetraenoic acid [HETE]) over 3 years were significantly different between the placebo and pravastatin-treated groups, with the pravastatin group showing a lower rate of biomarker increase. Urinary 8-HETE, 9-HETE, and 11-HETE were positively associated with the changes in HtTKV in the pravastatin group. CONCLUSIONS:Pravastatin therapy diminished the increase of cyclooxygenase- and lipoxygenase-derived plasma lipid mediators. The identified biomarkers and related molecular pathways of inflammation and endothelial dysfunction may present potential targets for monitoring of disease severity and therapeutic intervention of autosomal dominant polycystic kidney disease.
RCT Entities:
BACKGROUND AND OBJECTIVES: Disease-specific treatment options for autosomal dominant polycystic kidney disease are limited. Clinical intervention early in life is likely to have the greatest effect. In a 3-year randomized double-blind placebo-controlled phase 3 clinical trial, the authors recently showed that pravastatin decreased height-corrected total kidney volume (HtTKV) progression of structural kidney disease over a 3-year period. However, the underlying mechanisms have not been elucidated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants were recruited nationally from July 2007 through October 2009. Plasma and urine samples collected at baseline, 18 months, and 36 months from 91 pediatric patients enrolled in the above-mentioned clinical trial were subjected to mass spectrometry-based biomarker analysis. Changes in biomarkers over 3 years were compared between placebo and pravastatin-treated groups. Linear regression was used to evaluate the changes in biomarkers with the percent change in HtTKV over 3 years. RESULTS: Changes in plasma concentrations of proinflammatory and oxidative stress markers (9- hydroxyoctadecadienoic acid, 13-hydroxyoctadecadienoic acid, and 15-hydroxyeicosatetraenoic acid [HETE]) over 3 years were significantly different between the placebo and pravastatin-treated groups, with the pravastatin group showing a lower rate of biomarker increase. Urinary 8-HETE, 9-HETE, and 11-HETE were positively associated with the changes in HtTKV in the pravastatin group. CONCLUSIONS:Pravastatin therapy diminished the increase of cyclooxygenase- and lipoxygenase-derived plasma lipid mediators. The identified biomarkers and related molecular pathways of inflammation and endothelial dysfunction may present potential targets for monitoring of disease severity and therapeutic intervention of autosomal dominant polycystic kidney disease.
Authors: Albert W Dreisbach; Stanley V Smith; Patrick B Kyle; Manjunath Ramaiah; Margaret Amenuke; Michael R Garrett; Seth T Lirette; Michael E Griswold; Richard J Roman Journal: Prostaglandins Other Lipid Mediat Date: 2014-08-22 Impact factor: 3.072
Authors: Vicente E Torres; Jared J Grantham; Arlene B Chapman; Michal Mrug; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Diego Martin; Mark E Lockhart; William M Bennett; Marva Moxey-Mims; Kaleab Z Abebe; Yan Lin; James E Bost Journal: Clin J Am Soc Nephrol Date: 2010-11-18 Impact factor: 8.237
Authors: Melissa A Cadnapaphornchai; Diana M George; Kim McFann; Wei Wang; Berenice Gitomer; John D Strain; Robert W Schrier Journal: Clin J Am Soc Nephrol Date: 2014-04-10 Impact factor: 8.237
Authors: Iram Zafar; Yunxia Tao; Sandor Falk; Kimberly McFann; Robert W Schrier; Charles L Edelstein Journal: Am J Physiol Renal Physiol Date: 2007-06-20
Authors: Nikolaos Psychogios; David D Hau; Jun Peng; An Chi Guo; Rupasri Mandal; Souhaila Bouatra; Igor Sinelnikov; Ramanarayan Krishnamurthy; Roman Eisner; Bijaya Gautam; Nelson Young; Jianguo Xia; Craig Knox; Edison Dong; Paul Huang; Zsuzsanna Hollander; Theresa L Pedersen; Steven R Smith; Fiona Bamforth; Russ Greiner; Bruce McManus; John W Newman; Theodore Goodfriend; David S Wishart Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240
Authors: Yuriko Adkins; Benjamin J Belda; Theresa L Pedersen; Dawn M Fedor; Bruce E Mackey; John W Newman; Darshan S Kelley Journal: Lipids Date: 2017-04-13 Impact factor: 1.880
Authors: Godela M Brosnahan; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Charity G Patterson; Kyongtae T Bae; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Ronald D Perrone; Theodore I Steinman; Vicente E Torres Journal: Curr Hypertens Rev Date: 2017
Authors: Jost Klawitter; Cristina Sempio; Matthew J Jackson; Peter H Smith; Katharina Hopp; Michel Chonchol; Berenice Y Gitomer; Uwe Christians; Jelena Klawitter Journal: Am J Nephrol Date: 2022-03-09 Impact factor: 4.605
Authors: Jesse D Hinckley; Laura Saba; Kristen Raymond; Karsten Bartels; Jost Klawitter; Uwe Christians; Christian Hopfer Journal: Cannabis Cannabinoid Res Date: 2020-06-19
Authors: Charlotte Gimpel; Carsten Bergmann; Detlef Bockenhauer; Luc Breysem; Melissa A Cadnapaphornchai; Metin Cetiner; Jan Dudley; Francesco Emma; Martin Konrad; Tess Harris; Peter C Harris; Jens König; Max C Liebau; Matko Marlais; Djalila Mekahli; Alison M Metcalfe; Jun Oh; Ronald D Perrone; Manish D Sinha; Andrea Titieni; Roser Torra; Stefanie Weber; Paul J D Winyard; Franz Schaefer Journal: Nat Rev Nephrol Date: 2019-11 Impact factor: 28.314